Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosisDenali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiationDevelopment of RIPK1 inhibitor program continues in a broad range of ...

Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinsons diseaseFurther validation and expansion of Transport Vehicle (TV) technology, including multiple interim clinical data readouts, submission of IND for additional ETV program, and ...

Denali Therapeutics Inc. (NASDAQ:DNLI Get Rating) Director Marc Tessier-Lavigne sold 20,000 shares of the stock in a transaction that occurred on Wednesday, November 23rd. The shares were sold at an average price of $30.48, for a total value of $609,600.00. Following the transaction, the director ...

Denali Therapeutics Inc. (NASDAQ:DNLI Get Rating) Director Marc Tessier-Lavigne sold 20,000 shares of the stock in a transaction that occurred on Wednesday, November 23rd. The shares were sold at an average price of $30.48, for a total value of $609,600.00. Following the transaction, the ...

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its common stock at a price to the public of $26.50 per share. All of the shares are to be sold by Denali ...